Literature DB >> 22730392

Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure.

Anthony G Garcia1, Richard M Wilson, Joline Heo, Namita R Murthy, Simoni Baid, Noriyuki Ouchi, Flora Sam.   

Abstract

Diastolic heart failure (HF) accounts for up to 50% of all HF admissions, with hypertension being the major cause of diastolic HF. Hypertension is characterized by left ventricular (LV) hypertrophy (LVH). Proinflammatory cytokines are increased in LVH and hypertension, but it is unknown if they mediate the progression of hypertension-induced diastolic HF. We sought to determine if interferon-γ (IFNγ) plays a role in mediating the transition from hypertension-induced LVH to diastolic HF. Twelve-week old BALB/c (WT) and IFNγ-deficient (IFNγKO) mice underwent either saline (n = 12) or aldosterone (n = 16) infusion, uninephrectomy, and fed 1% salt water for 4 wk. Tail-cuff blood pressure, echocardiography, and gene/protein analyses were performed. Isolated adult rat ventricular myocytes were treated with IFNγ (250 U/ml) and/or aldosterone (1 μM). Hypertension was less marked in IFNγKO-aldosterone mice than in WT-aldosterone mice (127 ± 5 vs. 136 ± 4 mmHg; P < 0.01), despite more LVH (LV/body wt ratio: 4.9 ± 0.1 vs. 4.3 ± 0.1 mg/g) and worse diastolic dysfunction (peak early-to-late mitral inflow velocity ratio: 3.1 ± 0.1 vs. 2.8 ± 0.1). LV ejection fraction was no different between IFNγKO-aldosterone vs. WT-aldosterone mice. LV end systolic dimensions were decreased significantly in IFNγKO-aldosterone vs. WT-aldosterone hearts (1.12 ± 0.1 vs. 2.1 ± 0.3 mm). Myocardial fibrosis and collagen expression were increased in both IFNγKO-aldosterone and WT-aldosterone hearts. Myocardial autophagy was greater in IFNγKO-aldosterone than WT-aldosterone mice. Conversely, tumor necrosis factor-α and interleukin-10 expressions were increased only in WT-aldosterone hearts. Recombinant IFNγ attenuated cardiac hypertrophy in vivo and modulated aldosterone-induced hypertrophy and autophagy in cultured cardiomyocytes. Thus IFNγ is a regulator of cardiac hypertrophy in diastolic HF and modulates cardiomyocyte size possibly by regulating autophagy. These findings suggest that IFNγ may mediate adaptive downstream responses and challenge the concept that inflammatory cytokines mediate only adverse effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22730392      PMCID: PMC3468473          DOI: 10.1152/ajpheart.00298.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  56 in total

1.  Developmental changes in left and right ventricular diastolic filling patterns in mice.

Authors:  Yu-Qing Zhou; F Stuart Foster; Robert Parkes; S Lee Adamson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06-12       Impact factor: 4.733

2.  Hemodynamic determinants of the time-course of fall in canine left ventricular pressure.

Authors:  J L Weiss; J W Frederiksen; M L Weisfeldt
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

3.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

4.  The progression from hypertension to congestive heart failure.

Authors:  D Levy; M G Larson; R S Vasan; W B Kannel; K K Ho
Journal:  JAMA       Date:  1996 May 22-29       Impact factor: 56.272

5.  Noninvasive indexes of cardiac systolic and diastolic function in hyperthyroid and senescent mouse.

Authors:  G E Taffet; C J Hartley; X Wen; T Pham; L H Michael; M L Entman
Journal:  Am J Physiol       Date:  1996-06

6.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

7.  Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.

Authors:  Theodore L Goodfriend; David A Calhoun
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

8.  Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.

Authors:  Takehiro Ogata; Takashi Miyauchi; Satoshi Sakai; Masakatsu Takanashi; Yoko Irukayama-Tomobe; Iwao Yamaguchi
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

9.  Thyroid-specific expression of IFN-gamma limits experimental autoimmune thyroiditis by suppressing lymphocyte activation in cervical lymph nodes.

Authors:  Jobert G Barin; Marina Afanasyeva; Monica V Talor; Noel R Rose; C Lynne Burek; Patrizio Caturegli
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

10.  Gamma-interferon corrects aberrant protein kinase C levels and immunosuppression in the spontaneously hypertensive rat.

Authors:  M D Sauro; J W Hadden
Journal:  Int J Immunopharmacol       Date:  1992-11
View more
  38 in total

1.  Synchronized age-related gene expression changes across multiple tissues in human and the link to complex diseases.

Authors:  Jialiang Yang; Tao Huang; Francesca Petralia; Quan Long; Bin Zhang; Carmen Argmann; Yong Zhao; Charles V Mobbs; Eric E Schadt; Jun Zhu; Zhidong Tu
Journal:  Sci Rep       Date:  2015-10-19       Impact factor: 4.379

2.  Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction.

Authors:  Liping Zhou; Adrian Filiberti; Mary Beth Humphrey; Christian D Fleming; Benjamin J Scherlag; Sunny S Po; Stavros Stavrakis
Journal:  Exp Physiol       Date:  2018-11-29       Impact factor: 2.969

3.  Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation.

Authors:  Mohamed A Saleh; William G McMaster; Jing Wu; Allison E Norlander; Samuel A Funt; Salim R Thabet; Annet Kirabo; Liang Xiao; Wei Chen; Hana A Itani; Danielle Michell; Tianxiao Huan; Yahua Zhang; Satoshi Takaki; Jens Titze; Daniel Levy; David G Harrison; Meena S Madhur
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

4.  Neuregulin-1β induces proliferation, survival and paracrine signaling in normal human cardiac ventricular fibroblasts.

Authors:  Annet Kirabo; Sergey Ryzhov; Manisha Gupte; Seng Sengsayadeth; Richard J Gumina; Douglas B Sawyer; Cristi L Galindo
Journal:  J Mol Cell Cardiol       Date:  2017-03-03       Impact factor: 5.000

Review 5.  Role of immune cells in hypertension.

Authors:  Antoine Caillon; Pierre Paradis; Ernesto L Schiffrin
Journal:  Br J Pharmacol       Date:  2018-07-20       Impact factor: 8.739

6.  Autophagy Portends the Level of Cardiac Hypertrophy in Experimental Hypertensive Swine Model.

Authors:  Xin Zhang; Matthew E Gibson; Zi-Lun Li; Xiang-Yang Zhu; Kyra L Jordan; Amir Lerman; Lilach O Lerman
Journal:  Am J Hypertens       Date:  2015-04-22       Impact factor: 2.689

Review 7.  Immune cell trafficking, lymphatics and hypertension.

Authors:  Dakshnapriya Balasubbramanian; Catalina A Lopez Gelston; Joseph M Rutkowski; Brett M Mitchell
Journal:  Br J Pharmacol       Date:  2018-06-25       Impact factor: 8.739

8.  Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension.

Authors:  Xin Zhang; Zi-Lun Li; John A Crane; Kyra L Jordan; Aditya S Pawar; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  Hypertension       Date:  2014-04-21       Impact factor: 10.190

Review 9.  Inflammation, immunity, and hypertensive end-organ damage.

Authors:  William G McMaster; Annet Kirabo; Meena S Madhur; David G Harrison
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

Review 10.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.